Expired Study
This study is not currently recruiting Study Participants on ClinicalConnection.com. If you would like to find active studies please search for clinical trials.

Houston, Texas 77030


This phase II trial is studying how well CCI-779 works in treating patients with relapsed or refractory chronic lymphocytic leukemia. Drugs used in chemotherapy, such as CCI-779, work in different ways to stop cancer cells from dividing so they stop growing or die

Study summary:

OBJECTIVES: I. Determine the activity of CCI-779 in patients with relapsed, refractory, or transformed chronic lymphocytic leukemia. OUTLINE: Patients are stratified according to disease (relapsed or refractory chronic lymphocytic leukemia [CLL] vs transformed CLL). Patients receive CCI-779 IV over 30 minutes on days 1, 8, 15, and 22. Treatment repeats every 28 days for up to 6 courses in the absence of disease progression or unacceptable toxicity. Patients achieving an objective response may receive 3 consolidation courses of therapy.


Inclusion Criteria: - Diagnosis of chronic lymphocytic leukemia (CLL) - Relapsed, refractory, or transformed disease - Relapsed disease defined as symptomatic loss of a prior partial or complete response to a regimen containing a purine analog and/or a monoclonal antibody AND evidence of disease progression - Primary resistant disease defined as failure to achieve an objective response to a regimen containing a purine analog and/or a monoclonal antibody - Transformed CLL (Richters transformation), must meet both of the following criteria: - Histologically confirmed lymphoma - Measurable disease - No CNS disease - Performance status - ECOG 0-2 - Bilirubin ≤ 2 mg/dL (unless elevated due to Gilbert's disease) - SGOT and SGPT < 3 times upper limit of normal - Creatinine ≤ 2 mg/dL (unless due to organ leukemic involvement) - No symptomatic congestive heart failure - No unstable angina pectoris - No cardiac arrhythmia - Not pregnant or nursing - Negative pregnancy test - Fertile patients must use effective contraception - HIV-positive patients allowed provide CD4 counts are normal and no AIDS-defining disease is present - No history of allergic reactions attributed to compounds of similar chemical or biological composition to CCI-779 - No ongoing or active infection - No psychiatric illness or social situation that would preclude study compliance - No other concurrent uncontrolled illness - See Disease Characteristics - No concurrent prophylactic hematopoietic colony-stimulating factors - See Disease Characteristics - More than 2 weeks since prior cytotoxic chemotherapy and recovered - More than 2 weeks since prior radiotherapy and recovered - No other concurrent investigational or antitumor agents - No other concurrent cytotoxic agents - No concurrent combination antiretroviral therapy for HIV-positive patients



Primary Contact:

Principal Investigator
Francis Giles
M.D. Anderson Cancer Center

Backup Contact:


Location Contact:

Houston, Texas 77030
United States

There is no listed contact information for this specific location.

Site Status: N/A

Data Source: ClinicalTrials.gov

Date Processed: October 09, 2019

Modifications to this listing: Only selected fields are shown, please use the link below to view all information about this clinical trial.

Click to view Full Listing

This study is not currently recruiting Study Participants on ClinicalConnection.com. The form below is not enabled.